PXS Stock Overview
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Pharmaxis Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.061 |
| 52 Week High | AU$0.11 |
| 52 Week Low | AU$0.054 |
| Beta | 0.47 |
| 1 Month Change | 0% |
| 3 Month Change | -7.58% |
| 1 Year Change | -39.00% |
| 3 Year Change | -46.96% |
| 5 Year Change | -77.82% |
| Change since IPO | -86.44% |
Recent News & Updates
Recent updates
We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely
Feb 28
Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why
Oct 27Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque
Mar 01We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth
Jan 04
Shareholder Returns
| PXS | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 1.7% | -5.0% | 0.3% |
| 1Y | -39.0% | -31.1% | 1.4% |
Return vs Industry: PXS underperformed the Australian Pharmaceuticals industry which returned -30.2% over the past year.
Return vs Market: PXS underperformed the Australian Market which returned 2.4% over the past year.
Price Volatility
| PXS volatility | |
|---|---|
| PXS Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.7% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: PXS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: PXS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 65 | Gary Phillips | https://www.pharmaxis.com.au |
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma.
Pharmaxis Ltd Fundamentals Summary
| PXS fundamental statistics | |
|---|---|
| Market Cap | AU$43.86m |
| Earnings (TTM) | AU$2.04m |
| Revenue (TTM) | AU$17.93m |
21.5x
P/E Ratio2.4x
P/S RatioIs PXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PXS income statement (TTM) | |
|---|---|
| Revenue | AU$17.93m |
| Cost of Revenue | AU$8.86m |
| Gross Profit | AU$9.07m |
| Other Expenses | AU$7.04m |
| Earnings | AU$2.04m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Apr 28, 2023
| Earnings per share (EPS) | 0.0028 |
| Gross Margin | 50.59% |
| Net Profit Margin | 11.36% |
| Debt/Equity Ratio | 0% |
How did PXS perform over the long term?
See historical performance and comparison